Fluphenazine

CHEMBL726 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

437.5 g/mol

LogP

4.4

Phase

4

This first-generation antipsychotic medication blocks dopamine receptors to reduce the hallucinations, delusions, and disorganized thinking of schizophrenia. It is available in oral and long-acting injectable forms and has been used for decades in psychiatric treatment.

Peso Molecular

437,5000 g/mol

LogP

4,40

TPSA

55,30 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Psoriasis Stroke Obesity

Mecanismo de Ação

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2

Molecular Formula

C22H26F3N3OS

HBD / HBA

1 / 8

Ligações Rotacionáveis

6

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This first-generation antipsychotic medication blocks dopamine receptors to reduce the hallucinations, delusions, and disorganized thinking of schizophrenia. It is available in oral and long-acting injectable forms and has been used for decades in psychiatric treatment.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL726. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3372. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Fluphenazine no PillFYI

Estrutura

Dados Rápidos

Fórmula: C22H26F3N3OS
Sinônimos: 3

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.